TetraPhase Pharmaceuticals, Inc. Garners $25,000,000 Series A Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=cf278e66-4f63-4e71-bda0-dcbb77e7771a&Preview=1 -
Date
11/27/2006 -
Company Name
TetraPhase Pharmaceuticals, Inc. -
Mailing Address
480 Arsenal Street Watertown, MA 02472 -
Company Description
Tetraphase Pharmaceuticas is focused on the discovery and development of new tetracycline antibiotics to treat drug resistant bacterial infections. The company’s approach capitalizes on ground-breaking technology, licensed from Harvard University (Dr. Andrew Myers, Professor of Chemistry and Chemical Biology), which enables for the first time the total synthesis of tetracyclines by enabling their synthesis from simple building blocks. The technology allows extensive modification of the core molecule and synthesis of thousands of new tetracycline compounds that were previously inaccessible, dramatically expanding the universe of an existing, highly successful antibiotic class. Tetraphase has an exlusive worldwide license to the technology. -
Website
http://www.tetraphasepharma.com/
-
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The company will develop new classes of antibiotics aimed at drug-resistant infections. -
M&A Terms
-
Venture Investor
Skyline Ventures -
Venture Investor
Fidelity BioSciences -
Venture Investor
CMEA Ventures -
Venture Investor
Mediphase Venture Partners -
Venture Investor
Flagship Ventures
